. 2023 Feb 25;43(5):951–964. doi: 10.1007/s10875-022-01426-y

Table 2.

Pegademase dose adjustment and elapegademase dosage

	Screening	Lead-In Phase		Treatment and Maintenance Phase
Patient	Pegademase regimen, no. of injections/week	Pegademase, U/kg^a		Elapegademase, mg/kg^b	Treatment duration, years	Elapegademase self-dosing^c
Patient	Pegademase regimen, no. of injections/week	Start	End	Elapegademase, mg/kg^b	Treatment duration, years	Elapegademase self-dosing^c
1^d	2	43.9	43.4	0.28	0.1	No
2	2	28.2	27.9	0.19	4.2	Yes
3	1	29.6	36.1	0.23	2.4	No
4	2	7.7	30.0	0.20	4.2	No
5	1	31.3	32.2	0.21	2.4	No
6	2	42.9	44.1	0.29	2.1	Yes
7	3	21.6	26.2	0.17	1.4	Yes

^aTotal dose for the week

^bElapegademase dosage was based on pegademase dosage, using a conversion factor for enzyme equivalent activity

^cElapegademase self-dosing at home was allowed during the Treatment Phase from weeks 12, 14, 16, 18, and 20 and during the Maintenance Phase until the end of the study

^dPatient 1 received 2 doses of elapegademase and withdrew due to a treatment-emergent adverse effect

1 mg elapegademase = 150 U pegademase